Presentation is loading. Please wait.

Presentation is loading. Please wait.

Presented by: Katarina Bojanić

Similar presentations


Presentation on theme: "Presented by: Katarina Bojanić"— Presentation transcript:

1 Presented by: Katarina Bojanić
Mentor: A. Žmegač Horvat

2 FACTS & EPIDEMIOLOGY Most common malignancy in women (25-30%)
2nd leading cause of cancer deaths (after lung c.) > 570,000 new cases worldwide each year 2,300 new cases >800 deaths in Croatia (2005)

3 One out of eight women will be diagnosed
Strikes a small percentage of men ≈1,500 new cases expected to be diagnosed in men next year

4 Every three minutes a woman in the US is diagnosed with BC
Every 12 minutes a woman dies from BC All women are at risk (rare in women <40; 10% of palpable masses malignant)

5 Female Breast Anatomy Each breast = 15 to 20 sections (lobes) arranged like petals of daisy Inside lobe = smaller structures (lobules) End of each lobule = tiny sacs (bulbs), produce milk

6 Lobes, lobules, bulbs- linked by network of thin tubes (ducts)
Carry milk: bulbs → dark area of skin (areola) Duct Areola Breast profile A ducts B lobules C dilated section of duct to hold milk D nipple E fat F pectoralis major muscle G chest wall/rib cage Enlargement A normal duct cells B basement membrane (duct wall) C lumen (center of duct)

7 Risk Factors Gender Age, Race Weight (obesity)
Nonmodifiable risks Modifiable risks Gender Age, Race Family/Personal history of BC Genetic factors Menstrual history Certain types of breast disease Radiation Weight (obesity) Exercise Alcohol Reproductive history Hormone replacement therapy Oral contraceptive use Breastfeeding

8 Genetic risk factors →10 % of BC familial (hereditary)
BRCA 1 & BRCA 2 → tumor suppressor genes (breast cancer gene) →role in cellular DNA repair →mutation increases risk P53, RAS, C-MYC, RB gene

9 Noninvasive Cancers (in situ)
Types of Breast Cancer Invasive Cancers Noninvasive Cancers (in situ) spread from ducts or lobes into fatty tissue limited to ducts or lobes & does not spread into fatty tissue

10 Detection methods Self breast exam Clinical examination
Mammography > 35 Ultrasound < 35 Biopsy if indicated

11 Mammography X-ray picture of the breast to detect breast cancer
Detects a breast lump before it can be felt Age Frequency of Mammogram 40 1-2 year 50 Every year <49 with family hy of breast cancer Consult health care providers about risks Slide 21 A mammogram is an x-ray of the breast. The modern mammogram uses x-rays especially designed for the breast and uses very low levels of radiation. Mammograms are a very important part of breast cancer screening as they can detect small breast cancers before they can be felt and can reduce the risk of dying from the disease. References: NCI CancerNet: What you need to know about breast cancer CancerCare Inc. Patient Briefs: A mammogram can help save your life

12 BIOPSY RESULTS 80% of all breast biopsies turn out to be benign

13 Clinical Breast Exam Performed by doctor Every 3 y. for women 20 – 39
Yearly for women > 40 yrs of age Slide 20 Breast self-examination or BSE is an examination a woman does of her own breasts, which the American Cancer Society recommends monthly for women over 20 years of age. Changes that should be reported to a physician include a lump or thickening in the breast or under the arm, a change in breast size or shape, fluid coming from the nipple, or any change in the breast skin. A clinical breast examination is an exam of the breast conducted by a health care professional, recommended every three years in women between ages 20 and 39 and annually in women over age 40. Mammography is recommended by ACS annually from age 40 on. Reference: American Cancer Society Website: Breast Cancer Resource Center: Detection and Symptoms

14 Breast Self-Exam Monthly starting at the age of 20! Still menstruating
2-3 days after period ends No longer menstruating same day every month

15 Two parts of BSE 1) Visual 2) Palpatory:
Examine each breast separately Use pads of middle three fingers; feel the texture Examine the armpits

16 Patterns

17 Visual: Discharge or bleeding.
Most common: Lump or thickening in breast. Often painless Discharge or bleeding. Redness or pitting of skin over the breast; like the skin of an orange. Change in size or contours of breast. Change in color or appearance of areola.

18 Abnormal Breast Changes
Lump in the breast Changes in breast size of shape Notify Your Doctor Nipple discharged or tenderness Changes in the skin of the breast

19 TREATMENT OPTIONS & PROGNOSIS
Depend on Size of the tumor Invasive or in situ Histologic type - ductal (85%) vs. lobular Estrogen/progesterone receptors (60-70%positive) Her-2/ neu status (receptor for epidermal growth f.) tm size increases- chance decreases SURVIVAL

20 Lymph node status Spread to other parts of the body (bones, liver, lung, brain) Age (premenopausal = poor prognostic factor)

21 TREATMENT Surgery Radiation Therapy (local) Chemotherapy (systemic)
Goals Cure, Control, Palliation Surgery Radiation Therapy (local) Chemotherapy (systemic) Hormonal Therapy (systemic) Immunotherapy 􀂄 Therapy is individualized

22 SURGERY Mastectomy (complete/radical) Breast conservation (partial)

23 RECONSTRUCTION

24 RADIATION THERAPY Local control of disease Indications:
Adjuvant (after partial mastectomy) Young patients with DCIS High risk of local recurrence High energy rays used to kill cancer cells

25 CHEMOTHERAPY Anticancer drugs = systemic control of disease
Indications: After surgery to reduce risk of recurrence Large + locally advanced cancer to reduce the size prior to surgery (neoadjuvant) Metastatic - to reduce cancer that has spread + relieve symptoms & prolong life

26 HORMONAL THERAPY Hormones (blood stream) → attach ca. cells, promote their growth Block the receptor or production of hormones ! Side effects: hot flashes, depression, ↑ risk of uterine cancer, induced manopause, blood clots Tamoxifen, aromatase inhibitors...

27 IMMUNOTHERAPY Monoclonal antibodies Trastuzumab/Herceptin
Patients whose cancer cells over-express Her-2-neu oncogene as measured by IHC or FISH (25 to 30% of patients)

28 Through early detection and improved treatments more women than ever are surviving breast cancer...

29 Questions ? THANK YOU FOR YOUR ATTENTION!

30 References: Kusić Z.Onkologija.Zagreb,2008
Damjanov I, Jukić S, Nola M.Patologija.Medicinska naklada,Zagreb, 2008 Kumar P, Clark M.Clinical Medicine.Saunders Elsevier,London,2007


Download ppt "Presented by: Katarina Bojanić"

Similar presentations


Ads by Google